

## The Acute Action of Ammonia on Rat Brain Metabolism *in vivo*

By RICHARD A. HAWKINS, ALEXANDER L. MILLER, RICHARD C. NIELSEN  
and RICHARD L. VEECH

Section on Neurochemistry, National Institute of Mental Health, and the National Institute of Alcohol Abuse and Alcoholism, Saint Elizabeths Hospital, Washington, D.C. 20032, U.S.A.

(Received 27 March 1973)

1. Acute  $\text{NH}_4^+$  toxicity was studied by using a new apparatus that removes and freezes the brains of conscious rats within 1 s. 2. Brains were removed and frozen 5 min after intraperitoneal injection of ammonium acetate (2–3 min before the onset of convulsions). Arterial  $[\text{NH}_4^+]$  rose from less than 0.01 to 1.74 mM at 4–5 min. The concentrations of all glycolytic intermediates measured, except glucose 6-phosphate, were increased by the indicated percentage above the control value as follows: glucose (by 41%), fructose 1,6-diphosphate (by 133%), dihydroxyacetone phosphate (by 164%),  $\alpha$ -glycerophosphate (by 45%), phosphoenolpyruvate (by 67%) and pyruvate (by 26%). 4. Citrate and  $\alpha$ -oxoglutarate concentrations were unchanged and that of malate was increased (by 17%). 5. Adenine nucleotides and  $\text{P}_i$  concentrations were unchanged but the concentration of creatine phosphate decreased slightly (by 6%). 6. Brain  $[\text{NH}_4^+]$  increased from 0.2 to 1.53 mM. Net glutamine synthesis occurred at an average rate of 0.33  $\mu\text{mol}/\text{min}$  per g. 7. The rate of brain glucose utilization was measured *in vivo* as 0.62  $\mu\text{mol}/\text{min}$  per g in controls and 0.81  $\mu\text{mol}/\text{min}$  per g after  $\text{NH}_4^+$  injection. 8. The arteriovenous difference of glucose and  $\text{O}_2$  increased by 35%. 9. No significant arteriovenous differences of glutamate or glutamine were detected. Thus, although much  $\text{NH}_4^+$  was incorporated into glutamine the latter was not rapidly released from the brain to the circulation. 10. Plasma  $[\text{K}^+]$  increased from 3.3 to 5.4 mM. 11. The results indicate that  $\text{NH}_4^+$  stimulates oxidative metabolism but does not interfere with brain energy balance. The increased rate of oxidative metabolism could not be accounted for only on the basis of glutamine synthesis. We suggest that increased extracellular  $[\text{NH}_4^+]$  and  $[\text{K}^+]$  decreased the resting transmembrane potential and stimulated  $\text{Na}^+, \text{K}^+$ -stimulated adenosine triphosphatase activity thus accounting for the increased metabolic rate.

Increased blood  $[\text{NH}_4^+]$  may result in coma after extended periods, whereas an acute increase to relatively high concentrations causes convulsions (McIlwain & Bachelard, 1971). Within brain  $\text{NH}_4^+$  is removed by reductive amination of  $\alpha$ -oxoglutarate and amidation of glutamate to form glutamine (Weil-Malherbe, 1962; Berl, 1971). It was initially suggested that toxicity was due to depletion of citric acid-cycle intermediates (Recknagel & Potter, 1951; Bessman & Bessman, 1955). However, studies of acute  $\text{NH}_4^+$  toxicity in anaesthetized animals have shown no change in  $[\alpha\text{-oxoglutarate}]$  in brain (Hindfelt & Siesjö, 1971) and an increased rate of  $\text{CO}_2$  fixation (Berl *et al.*, 1962; Waelsch *et al.*, 1964) probably through pyruvate carboxylase (Felicoli *et al.*, 1966). Suggestions that  $\text{NH}_4^+$  interferes with energy stores by various means (Schenker *et al.*, 1967; Clarke, 1971) seem unlikely as recent results have shown no change in cerebral ATP concentration after acute  $\text{NH}_4^+$  administration to rats (Hindfelt & Siesjö, 1971).

The development of a new instrument, the brain-freezer, which removes and freezes rat brain within

1 s, has permitted study of  $\text{NH}_4^+$  toxicity in conscious rats (Veech *et al.*, 1973). The metabolic derangements accompanying acute  $\text{NH}_4^+$  toxicity were examined more closely than ever before by measuring key intermediates of the glycolytic pathway and citric acid cycle, indicators of the energy state and representative amino acids in brains of unanaesthetized rats.

### Materials and Methods

#### Materials

**Rats.** Male albino rats of the Wistar–Furth strain weighing about 225 g were from Carworth, New York, N.Y., U.S.A. All rats were starved for 48 h before experimentation.

**Reagents.** Enzymes and co-enzymes were from Boehringer Mannheim Corp., New York, N.Y., U.S.A. Glutaminase, prepared from pig kidney (Kvamme *et al.*, 1970), was kindly given by Dr. H. Weil-Malherbe. All other chemicals were of reagent grade.

### Methods

**Analytical methods.** Metabolites were determined spectrophotometrically or fluorimetrically by enzymic techniques: ADP and AMP (Adam, 1963); ATP (Lamprecht & Trautschold, 1963); alanine (Pfleiderer, 1963a);  $\text{NH}_4^+$  (Kirsten *et al.*, 1963); aspartate (Pfleiderer, 1963b); citrate (Moellering & Gruber, 1966); creatine phosphate (Lowry *et al.*,

**Brain utilization of glucose *in vivo*.** The rate of glucose utilization was measured by a technique based on that described by Gaitonde (1965). Briefly, the accumulation of  $^{14}\text{C}$  in the acid-soluble fraction of brain (excluding glucose) is measured after a single intravenous injection of  $[2\text{-}^{14}\text{C}]\text{glucose}$ . The rate of glucose utilization is calculated according to the equation:

$$\text{Rate of glucose utilization } (\mu\text{mol}/\text{min per g}) = \frac{{}^{14}\text{C accumulated in brain (d.p.m./g)}}{\int_0^t \text{glucose specific radioactivity (d.p.m.} \cdot \text{min} \cdot \mu\text{mol}^{-1})}$$

1964); glycogen (Lowry & Passonneau, 1972a); fructose 1,6-diphosphate and dihydroxyacetone phosphate (Bücher & Hohorst, 1963); glucose (Slein, 1963); glucose 6-phosphate (Hohorst, 1963a); glutamate (Bernt & Bergmeyer, 1963);  $\alpha$ -glycerophosphate (Hohorst, 1963b); lactate (Hohorst, 1963c); malate (Hohorst, 1963d);  $\alpha$ -oxoglutarate (Bergmeyer & Bernt, 1963)  $\text{O}_2$  (Van Slyke & Neil, 1924); phosphate (Guynn *et al.*, 1972); phosphoenolpyruvate (Lowry & Passonneau, 1972b); pyruvate (Bücher *et al.*, 1963). Where possible, several metabolites were determined in the same cuvette by sequential addition of the appropriate enzymes (lactate, malate and  $\alpha$ -glycerophosphate; dihydroxyacetone phosphate, fructose 1,6-diphosphate,  $\alpha$ -oxoglutarate and pyruvate). Labile metabolites were measured immediately after extraction and the extracts were deep-frozen ( $-90^\circ\text{C}$ ). The remaining metabolites were determined within a few days.

Glutamine measurement presented special difficulties (see Lund, 1970). Poor recoveries were obtained because of contamination of commercial glutaminase with glutamate decarboxylase (Sigma grade IV and to a lesser but significant extent Sigma grade V). However, glutaminase prepared from pig kidney (Kvamme *et al.*, 1970) had no glutamate decarboxylase activity. The incubation mixture had final concentrations of 100 mM-potassium phosphate buffer, pH 9.0, 10 mM-dithiothreitol, 2 mM-EDTA, 0.25 mg of enzyme/ml (3.5 units/mg) and up to 0.5 mM-glutamine. The samples were incubated at  $25^\circ\text{C}$  for 1 h and then centrifuged at 1000g to remove debris. A portion was removed and assayed for glutamate. Recovery of added glutamine was quantitative.

**Removal and treatment of brain.** The supratentorial portion of the brain was removed and frozen within 1 s (Veech *et al.*, 1973). The brain samples were ground under liquid  $\text{N}_2$  and extracted as described by Nelson *et al.* (1966) for all metabolites except  $\text{P}_i$ , which was determined after methanol extraction (Hawkins *et al.*, 1973) to avoid  $\text{P}_i$  contamination by bone.

On the basis of the assumption that brain cell and plasma glucose rapidly equilibrate, the integral was evaluated by plotting plasma glucose specific radioactivity against time and measuring the area beneath the curve by planimetry.

### Results

#### *Blood $\text{NH}_4^+$ concentrations*

$[\text{NH}_4^+]$  is normally in the range 0.002–0.007 mM in rat blood (Lund *et al.*, 1970; Williams *et al.*, 1972). At 4–5 min after intraperitoneal injection of ammonium acetate the concentration rose to 1.74 mM (Table 1). Between 7 and 10 min the rats convulsed.

#### *Blood gases and pH*

Blood pH remained constant after  $\text{NH}_4^+$  injection, although arterial  $\text{CO}_2$  pressure dropped markedly (Table 2). This may have resulted from the more rapid penetration of  $\text{NH}_4^+$  into tissues as compared with acetate resulting in decreased plasma  $[\text{HCO}_3^-]$  (Webster & Gabusda, 1958; Hindfelt & Siesjö, 1971).

#### *Arteriovenous differences of metabolites across brain*

The mean arteriovenous difference of glucose and  $\text{O}_2$  were increased 35% and 33% respectively above the control values (Table 3). The quantity of  $\text{O}_2$  removed from blood was in excess of that required to combust all glucose by about 20%. The additional fuel required was probably supplied by ketone bodies, not measured in these experiments, which can account for this quantity in 48 h-starved rats (Hawkins *et al.*, 1971). Little, if any, glucose removed from the blood was converted into blood lactate by normal rats (4%), whereas 13% was converted after  $\text{NH}_4^+$  injection. The arteriovenous difference of  $[\text{NH}_4^+]$  was 0.57 mM at 4–5 min whereas arteriovenous differences of glutamate and glutamine were undetectable.

Table 1. Concentrations of metabolites in arterial and venous blood across the brain

The values are means ( $\pm$ S.E.M.) with the number of observations indicated in parentheses. Arteriovenous differences were measured across brain of conscious rats as described by Hawkins & Veech (1973). For other details see the Materials and Methods section.

Treatment and time	Blood sample	[Glucose] (mM)	[Lactate] (mM)	[NH <sub>4</sub> <sup>+</sup> ] (mM)	[Glutamate] (mM)	[Glutamine] (mM)
None	Artery	5.10 $\pm$ 0.22	2.64 $\pm$ 0.38	<0.01	0.141 $\pm$ 0.008	0.982 $\pm$ 0.028
	Vein	4.53 $\pm$ 0.19	2.68 $\pm$ 0.37	<0.01	0.141 $\pm$ 0.008	0.994 $\pm$ 0.034
Ammonium acetate injected 4–5 min (8)	Artery	5.74 $\pm$ 0.21	3.20 $\pm$ 0.45	1.74 $\pm$ 0.19	0.124 $\pm$ 0.008	1.06 $\pm$ 0.04
	Vein	4.97 $\pm$ 0.16	3.43 $\pm$ 0.52	1.08 $\pm$ 0.10	0.128 $\pm$ 0.008	1.07 $\pm$ 0.03

Table 2. Blood gases and pH after ammonium acetate injection

The values are means ( $\pm$ S.E.M.) of four individual measurements. For other details see the Materials and Methods section.

Treatment and time	Blood sample	pH	CO <sub>2</sub>		O <sub>2</sub> (mM)
			(kPa)	(Torr)	
None	Artery	7.44 $\pm$ 0.009	5.38 $\pm$ 0.27	(40.4 $\pm$ 2.0)	8.46 $\pm$ 0.24
	Vein	7.37 $\pm$ 0.003	6.67 $\pm$ 0.11	(50.1 $\pm$ 0.8)	4.22 $\pm$ 0.28
Ammonium acetate injected 4–5 min	Artery	7.49 $\pm$ 0.026	3.46 $\pm$ 0.15	(26.0 $\pm$ 1.1)	8.36 $\pm$ 0.22
	Vein	7.37 $\pm$ 0.004	5.81 $\pm$ 0.21	(43.6 $\pm$ 1.6)	2.70 $\pm$ 0.56

Table 3. Arteriovenous differences of metabolites across the brain

The values are means ( $\pm$ S.E.M.) of the arteriovenous differences and are derived from the experiments contained in Table 1. The symbols + and – indicate appearance or removal of a metabolite and the symbols \* and \*\* indicate the statistical significance of the arteriovenous differences at the 5% and 1% levels respectively as compared with controls. For other details see Table 1.

Treatment and time	[Glucose] (mM)	[Lactate] (mM)	[NH <sub>4</sub> <sup>+</sup> ] (mM)	[Glutamate] (mM)	[Glutamine] (mM)	[O <sub>2</sub> ] (mM)
None	–0.57 $\pm$ 0.05	+0.04 $\pm$ 0.04	—	0.000 $\pm$ 0.005	+0.011 $\pm$ 0.04	4.23 $\pm$ 0.16
0min						
Ammonium acetate injected 4–5 min	–0.77 $\pm$ 0.07*	+0.23 $\pm$ 0.10**	–0.57 $\pm$ 0.12**	+0.004 $\pm$ 0.003	+0.02 $\pm$ 0.04	5.64 $\pm$ 0.50*

#### Brain glucose utilization

Brain glucose utilization was 0.624  $\pm$  0.026 (S.E.M.)  $\mu$ mol/min per g in control rats and increased by 29% after NH<sub>4</sub><sup>+</sup> injection to 0.806  $\pm$  0.035. Values are the mean of nine individual determinations and the difference between the two groups of animals is statistically significant at the 1% level. From the rate of glucose utilization and the arteriovenous difference whole-brain blood flow may be calculated:

Thus by using the values given above and in Table 3, blood flow was about 1.1 ml/min per g in untreated rats and 1.05 ml/min per g after NH<sub>4</sub><sup>+</sup> injection.

#### Intermediary metabolites of brain

The brain content of glycogen was decreased and the concentrations of all the glycolytic intermediates, with the exception of glucose 6-phosphate, were raised

$$\text{Blood flow (ml/min per g)} = \frac{\text{glucose utilization } (\mu\text{mol/min per g})}{\text{arteriovenous difference } (\mu\text{mol/ml})}$$

substantially (Table 4). The concentrations of citrate and  $\alpha$ -oxoglutarate remained constant and the concentration of malate was increased. The calculated concentration of oxaloacetate decreased as a consequence of the decreased cytoplasmic  $[NAD^+]/[NADH]$  ratio (see below).

#### Unchanged energy balance of brain

There were no changes in the concentrations of adenine nucleotides or  $P_i$  and hence no change in the

phosphorylation state of the adenine nucleotides in the brain (Table 5). A slight decrease in the concentration of creatine phosphate was found.

#### $NH_4^+$ and amino acid content of brain

The concentration of  $NH_4^+$  in brain rose from 0.2 to 1.53 mM. Much  $NH_4^+$  was incorporated into glutamine (1.65  $\mu$ mol/g) and a lesser amount into alanine (Table 6). The concentration of aspartate was decreased, consistent with the lowered concentration

Table 4. Effect of ammonium acetate on the concentrations of glycolytic and citric acid-cycle intermediates in rat brain

The values are means ( $\pm$ S.E.M.) of six to eight individual determinations. The symbols \* and \*\* indicate statistical significance at the 5% and 1% levels respectively. Rats were injected intraperitoneally with 2M-ammonium acetate, pH 7 (10 mmol/kg body wt.), or an equivalent volume of 0.154M-NaCl and killed at 5 min. For other details see the Materials and Methods section. The oxaloacetate concentration was calculated from the formula:

$$[\text{Oxaloacetate}] = \frac{[\text{pyruvate}] \times [\text{malate}]}{[\text{lactate}]} \times \frac{K_{\text{MDH}}}{K_{\text{LDH}}}$$

where  $K_{\text{MDH}}$  and  $K_{\text{LDH}}$  are the equilibrium constants of lactate dehydrogenase and malate dehydrogenase respectively (Williamson *et al.*, 1967).

Metabolite	Concn. in control (mM)	Concn. after injection of ammonium acetate (mM)
Glycogen	2.80 $\pm$ 0.05	2.00 $\pm$ 0.13**
Glucose	0.745 $\pm$ 0.044	1.05 $\pm$ 0.07**
Glucose 6-phosphate	0.154 $\pm$ 0.004	0.150 $\pm$ 0.004
Fructose 1,6-diphosphate	0.009 $\pm$ 0.001	0.021 $\pm$ 0.002**
Dihydroxyacetone phosphate	0.011 $\pm$ 0.001	0.029 $\pm$ 0.003**
$\alpha$ -Glycerophosphate	0.081 $\pm$ 0.002	0.129 $\pm$ 0.004**
Phosphoenolpyruvate	0.003 $\pm$ 0.0005	0.005 $\pm$ 0.0005*
Pyruvate	0.099 $\pm$ 0.003	0.125 $\pm$ 0.005**
Lactate	1.25 $\pm$ 0.05	2.39 $\pm$ 0.11**
Citrate	0.319 $\pm$ 0.004	0.302 $\pm$ 0.010
$\alpha$ -Oxoglutarate	0.208 $\pm$ 0.007	0.204 $\pm$ 0.007
Malate	0.249 $\pm$ 0.006	0.291 $\pm$ 0.006**
Oxaloacetate	0.0049 $\pm$ 0.0001	0.0038 $\pm$ 0.0001**

Table 5. Effect of ammonium acetate injection on adenine nucleotide and creatine phosphate concentrations of brain

The values are means ( $\pm$ S.E.M.) of six to eight determinations. The symbol \* indicates statistical significance at the 5% level. For other details see Table 4.

Metabolite	Concn. in control (mM)	Concn. after injection of ammonium acetate (mM)
ATP	2.49 $\pm$ 0.03	2.48 $\pm$ 0.03
ADP	0.556 $\pm$ 0.013	0.544 $\pm$ 0.010
AMP	0.051 $\pm$ 0.002	0.056 $\pm$ 0.001
Creatine phosphate	4.12 $\pm$ 0.07	3.86 $\pm$ 0.04*
$P_i$	2.03 $\pm$ 0.05	2.13 $\pm$ 0.07
$\frac{[\text{ATP}]}{[\text{ADP}][\text{HPO}_4^{2-}]}$ ( $\text{mM}^{-1}$ )	3.90 $\pm$ 0.11	3.62 $\pm$ 0.08

of oxaloacetate available for transamination and maintenance of equilibrium with  $\alpha$ -oxoglutarate and glutamate (Duffy *et al.*, 1972; Miller *et al.*, 1973).

#### Redox state changes of brain

The cytoplasmic  $[NAD^+]/[NADH]$  ratio, calculated from the reactants of lactate dehydrogenase, was markedly decreased from 717 to 471 (Table 7). This decrease was not reflected by the reactants of  $\alpha$ -glycerophosphate dehydrogenase, probably because

of the low activity of this enzyme in brain (Balázs, 1970).

The removal of  $NH_4^+$  by brain is catalysed by glutamate dehydrogenase. Although there was a large increase in  $[NH_4^+]$ , there was no change in  $\alpha$ -oxoglutarate or glutamate concentrations. Assuming glutamate dehydrogenase to be near equilibrium in brain (Miller *et al.*, 1973), this indicated an increase in the mitochondrial  $[NAD^+]/[NADH]$  ratio. Whereas in general the redox states of the NAD couples change in parallel in the cytoplasm and mitochondria,

Table 6. Brain concentrations of some amino acids and  $NH_4^+$  after ammonium acetate injection

The values are means ( $\pm$ S.E.M.) of eight determinations. The symbol \*\* indicates statistical significance at the 1% level. For other details see Table 4.

Metabolite	Concn. in control (mM)	Concn. after injection of ammonium acetate (mM)
Glutamate	11.6 $\pm$ 0.1	11.3 $\pm$ 0.1
Glutamine	6.71 $\pm$ 0.2	8.36 $\pm$ 0.11**
Aspartate	2.75 $\pm$ 0.04	2.32 $\pm$ 0.06 **
Alanine	0.425 $\pm$ 0.022	0.574 $\pm$ 0.027**
$NH_4^+$	0.18 $\pm$ 0.03	1.53 $\pm$ 0.15**

Table 7. Redox state of brain nicotinamide nucleotide couples

The values are means ( $\pm$ S.E.M.) calculated from individual metabolite concentrations listed in Table 4. The symbol \*\* indicates statistical significance at the 1% level.  $[NADP^+]/[NADPH]$  ratios were calculated from the reactants of 'malic' enzyme ( $[NADP^+]/[NADPH] = [\text{pyruvate}][CO_2]/[\text{malate}]K$ ), and isocitrate dehydrogenase ( $[NADP^+]/[NADPH] = [\alpha\text{-oxoglutarate}][CO_2]/[\text{isocitrate}]K$ ), where the equilibrium constants were 34.4 mM and 1.17 M respectively (Krebs & Veech, 1969; Londesborough & Dalziel, 1968). Cytoplasmic and mitochondrial free  $[NAD^+]/[NADH]$  ratios were calculated from the reactants of lactate dehydrogenase ( $[NAD^+]/[NADH] = [\text{pyruvate}]/[\text{lactate}]K$ ), and glutamate dehydrogenase ( $[NAD^+]/[NADH] = [\alpha\text{-oxoglutarate}][NH_3]/[\text{glutamate}]K$ ), where the equilibrium constants were 0.111 mM and 3.87  $\mu$ M respectively (Williamson *et al.*, 1967). The concentration of isocitrate was assumed to be 5% that of citrate (Goldberg *et al.*, 1966) and brain tissue  $CO_2$  was taken to be 1.17 mM (Krebs & Veech, 1969).

Ratio	Control value	Value after injection of ammonium acetate
$[NAD^+]/[NADH]$ (lactate dehydrogenase)	717 $\pm$ 16	471 $\pm$ 11**
$10^3 \times [NADP^+]/[NADPH]$ (isocitrate dehydrogenase)	7.27 $\pm$ 0.21	7.57 $\pm$ 0.42
$10^3 \times [NADP^+]/[NADPH]$ ('malic' enzyme)	8.48 $\pm$ 0.21	7.93 $\pm$ 0.22
$[NAD^+]/[NADH]$ (glutamate dehydrogenase)	0.80 $\pm$ 0.13	7.06 $\pm$ 0.70**

Table 8.  $K^+$  and  $Na^+$  concentration of brain and plasma

All values are means ( $\pm$ S.E.M.) of four to six individual determinations. For other details see the Materials and Methods section. Brain concentration was calculated assuming an 80% water content and no correction was applied for extracellular contamination.

Treatment	Plasma $[K^+]$ (mM)	Plasma $[Na^+]$ (mM)	Brain $[K^+]$ (mM)
Control	3.3 $\pm$ 0.1	140 $\pm$ 1	116.0 $\pm$ 1.25
Ammonium acetate injected	5.4 $\pm$ 0.2	140 $\pm$ 1	115.0 $\pm$ 1.0

changes in opposite directions have been reported (Williamson *et al.*, 1967).

#### *Increased plasma [K<sup>+</sup>] after NH<sub>4</sub><sup>+</sup> administration*

In brain, and presumably other tissues, NH<sub>4</sub><sup>+</sup> may exchange with K<sup>+</sup> causing K<sup>+</sup> efflux (Vrba *et al.*, 1958; Tower *et al.*, 1961; Rybova, 1959). After ammonium acetate injection, plasma [K<sup>+</sup>] rose from 3.3 to 5.4 mol/l but no change of [Na<sup>+</sup>] occurred (Table 8).

### Discussion

#### *Incorporation of NH<sub>4</sub><sup>+</sup> into glutamine*

NH<sub>4</sub><sup>+</sup> taken up by brain is largely incorporated into glutamine (Weil-Malherbe, 1962; Berl, 1971), and we confirmed this. A quantitatively significant net increase in the incorporation of NH<sub>4</sub><sup>+</sup> into glutamate, aspartate or alanine did not occur. During the time-period studied there was no appreciable efflux from the brain of glutamine or glutamate. Thus if glutamine is the vehicle for removal of NH<sub>4</sub><sup>+</sup> from brain (Lund, 1971), this process is slow and restoration of normal concentrations of glutamine must require relatively long periods. This is emphasized by observations that rats with plasma [NH<sub>4</sub><sup>+</sup>] raised from 7 to 32 μM by porta-caval anastomosis had brain glutamine concentrations 250% those of controls after 6 weeks (Williams *et al.*, 1972).

#### *Increased oxidative metabolic rate caused by NH<sub>4</sub><sup>+</sup>*

Brain glucose utilization increased by 29% after NH<sub>4</sub><sup>+</sup> injection and arteriovenous differences of glucose and O<sub>2</sub> increased proportionately. The excess of energy produced from the increased rate of oxidative metabolism must have been consumed by a process that occurred as a consequence of increased [NH<sub>4</sub><sup>+</sup>]. Two possibilities are considered: incorporation of NH<sub>4</sub><sup>+</sup> into glutamine; and ionic effects of NH<sub>4</sub><sup>+</sup>.

#### *Synthesis of glutamine*

Although the synthesis of extra glutamine occurred at an average rate of 0.33 μmol/min per g, this does not necessarily explain the increased rate of oxidative metabolism. Glutamine may be synthesized from glucose and NH<sub>4</sub><sup>+</sup> by pathways present in rat brain (Felicoli *et al.*, 1966) by the following equation:



Thus NH<sub>4</sub><sup>+</sup> detoxification requires additional glucose but no increased oxidative metabolism with concomitant production of ATP. Glucose uptake from

blood was insufficient to supply substrate for glutamine since O<sub>2</sub> uptake was stoichiometric. The additional substrate required was approximately accounted for by glycogenolysis (0.16 μmol/min per g) and aspartate disappearance (0.09 μmol/min per g).

#### *Stimulation of Na<sup>+</sup>, K<sup>+</sup>-stimulated adenosine triphosphatase and oxidative metabolism by NH<sub>4</sub><sup>+</sup>*

The rate of cell energy metabolism is correlated with ion transport (Whittam & Wheeler, 1970). Stimulation of this process by increased [NH<sub>4</sub><sup>+</sup>] and the resulting rise in [K<sup>+</sup>] may account, at least in part, for the increased rate of oxidative metabolism observed. This effect could be brought about in two ways. First, in the presence of high [Na<sup>+</sup>], nerve Na<sup>+</sup>, K<sup>+</sup>-stimulated adenosine triphosphatase is stimulated by both NH<sub>4</sub><sup>+</sup> and K<sup>+</sup> with K<sub>m</sub> values of 5 and 1.8 mm respectively (Skou, 1960). The site of this effect is believed to be extracellular in nerve (Sjodin, 1971), as shown for erythrocytes (Whittam, 1964). By using the above constants and blood [NH<sub>4</sub><sup>+</sup>] and [K<sup>+</sup>] (Table 7) as an approximation of those existing in brain extracellular fluid an increase of 19% in Na<sup>+</sup>, K<sup>+</sup>-stimulated adenosine triphosphatase activity is predicted (Dixon & Webb, 1964). Secondly, Na<sup>+</sup>, K<sup>+</sup>-stimulated adenosine triphosphatase activity can also be influenced by the transmembrane potential. In frog muscle, decreases of about 20 mV result in a sharp increase in Na<sup>+</sup> efflux (Horowicz & Gerber, 1965). The resting transmembrane potential (*V*) may be calculated from:

$$V = -\frac{RT}{F} \ln \left( \frac{[\text{K}^+]_i + \alpha[\text{NH}_4^+]_i}{[\text{K}^+]_e + \alpha[\text{NH}_4^+]_e} \right)$$

Thus at rest:

$$V = -62 \log \left[ \frac{(116) + (0.2 \times 0.2)}{3.3 + (0.2 \times 0.007)} \right] = -96 \text{ mV}$$

After NH<sub>4</sub><sup>+</sup> injection:

$$V = -62 \log \left[ \frac{(115) + (0.2 \times 1.5)}{(5.4) + (0.2 \times 1.74)} \right] = -81 \text{ mV}$$

The subscripts *i* and *e* refer to intracellular and extracellular, respectively and  $\alpha$  ( $\alpha = 0.2$ ) is the permeability of NH<sub>4</sub><sup>+</sup> relative to K<sup>+</sup> (Binstock & Lecar, 1969). Thus, a decrease in the resting transmembrane potential of 15 mV is calculated. This agrees with direct measurements made on cat motor neurons and

squid giant axons (Lux *et al.*, 1970; Binstock & Lecar, 1969; Lorente de N6 *et al.*, 1957).

The convulsions produced by high [NH<sub>4</sub><sup>+</sup>] prob-

ably do not result from its incorporation into glutamine or the stimulation of oxidative metabolic rate as such. The increased flux through the various pathways resulting from these processes is well within the capacity of brain tissue. Generalized seizures that increase brain oxidative metabolism by 300–400% do not alter brain energy balance (Plum, 1971). A more likely mechanism of the pharmacological action of  $\text{NH}_4^+$  is the effect on the electrical properties of nerve cells. When presented extracellularly  $\text{NH}_4^+$ , like  $\text{K}^+$ , decreases the resting transmembrane potential (Lorente de N6 *et al.*, 1957; Binstock & Lecar, 1969; Lux *et al.*, 1970), therefore bringing the potential closer to the threshold for firing. This could cause a general increase in nerve-cell excitability and activity, resulting in convulsions.

The authors are grateful to Dr. Weil-Malherbe for guidance in the development of a reliable assay of glutamine, to Dr. J. V. Passonneau for patient demonstration of metabolite measurements by fluorimetric techniques and to Professor Sir Hans Krebs for kindly reading the manuscript.

## References

- Adam, H. (1963) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 573–577, Academic Press, New York
- Balázs, R. (1970) *Handb. Neurochem.* 3, 1–36
- Bergmeyer, H.-U. & Bernt, E. (1963) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 384–388, Academic Press, New York
- Berl, S. (1971) *Exp. Biol. Med.* 4, 71–84
- Berl, S., Takagaki, G., Clarke, D. D., & Waelsch, H. (1962) *J. Biol. Chem.* 237, 2570–2573
- Bernt, E. & Bergmeyer, H.-U. (1963) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 384–388, Academic Press, New York
- Bessman, S. P. & Bessman, A. N. (1955) *J. Clin. Invest.* 34, 622–628
- Binstock, L. & Lecar, H. (1969) *J. Gen. Physiol.* 53, 342–361
- Bücher, Th. & Hohorst, H. J. (1963) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 246–252, Academic Press, New York
- Bücher, Th., Czok, R., Lamprecht, W. & Latzko, E. (1963) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 253–259, Academic Press, New York
- Clarke, D. D. (1971) *Exp. Biol. Med.* 4, 80–84
- Dixon, M. & Webb, E. C. (1964) *Enzymes*, 2nd edn., p. 84, Longmans Green, London
- Duffy, T. E., Nelson, S. R. & Lowry, O. H. (1972) *J. Neurochem.* 19, 959–977
- Felicioli, R. A., Gabrielli, F. & Rossi, C. S. (1966) *Life Sci.* 6, 133–143
- Gaitonde, M. K. (1965) *Biochem. J.* 95, 803–810
- Goldberg, N. D., Passonneau, J. V. & Lowry, O. H. (1966) *J. Biol. Chem.* 241, 3997–4003
- Guynn, R. W., Veloso, D. & Veech, R. L. (1972) *Anal. Biochem.* 45, 277–285
- Hawkins, R. A. & Veech, R. L. (1973) in *Research Methods in Neurochemistry* (Marks, R. & Rodnight, R., eds.), Plenum Press, New York and London, in the press
- Hawkins, R. A., Williamson, D. H. & Krebs, H. A. (1971) *Biochem. J.* 122, 13–18
- Hawkins, R. A., Nielsen, R. C. & Veech, R. L. (1973) *J. Neurochem.* 20, 35–38
- Hindfelt, B. & Siesjö, B. K. (1971) *Scand. J. Clin. Lab. Invest.* 28, 365–374
- Hohorst, H. J. (1963a) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 134–138, Academic Press, New York
- Hohorst, H. J. (1963b) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 215–219, Academic Press, New York
- Hohorst, H. J. (1963c) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 266–270, Academic Press, New York
- Hohorst, H. J. (1963d) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 328–332, Academic Press, New York
- Horowicz, P. & Gerber, C. J. (1965) *J. Gen. Physiol.* 48, 489–514
- Kirsten, E., Gerez, C. & Kirsten, R. (1963) *Biochem. Z.* 337, 312–319
- Krebs, H. A. & Veech, R. L. (1969) in *The Energy Level and Metabolic Control in Mitochondria* (Papa, S., Tager, J. M., Quagliariello, E. & Slater, E. C., eds.), pp. 329–385, Adriatica Editrice, Bari
- Kvamme, E., Treit, B. & Svenneby, G. (1970) *J. Biol. Chem.* 245, 1871–1988
- Lamprecht, W. & Trautschold, I. (1963) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 543–551, Academic Press, New York
- Londesborough, J. C. & Dalziel, K. (1968) *Biochem. J.* 110, 217–222
- Lorente de N6, B., Ridal, F. & Larromend; L. M. H. (1957) *Nature (London)* 179, 737–738
- Lowry, O. H. & Passonneau, J. V. (1972a) *A Flexible System of Enzymatic Analysis*, pp. 189–193, Academic Press, New York
- Lowry, O. H. & Passonneau, J. V. (1972b) *A Flexible System of Enzymatic Analysis*, pp. 210–212, Academic Press, New York
- Lowry, O. H., Passonneau, J. V., Hasselberger, F. X. & Schulz, D. W. (1964) *J. Biol. Chem.* 239, 18–30
- Lund, P. (1970) in *Methoden der Enzymatischen Analyse* (Bergmeyer, H.-U., ed.), pp. 1670–1673, Verlag Chemie, Weinheim
- Lund, P. (1971) *Biochem. J.* 124, 653–660
- Lund, P., Brosnan, J. T. & Eggleston, L. V. (1970) in *Essays in Cell Metabolism* (Bartley, N., Kornberg, H. L. & Quayle, J. R., eds.), pp. 167–188, John Wiley and Sons Ltd., London
- Lux, H. D., Loracher, C. & Neher, E. (1970) *Exp. Brain Res.* 11, 431–447
- McIlwain, H. & Bachelard, H. S. (1971) *Biochemistry and the Central Nervous System*, 4th edn. pp. 196–197, Churchill, London
- Miller, A. L., Hawkins, R. A. & Veech, R. L. (1973) *J. Neurochem.* in the press
- Moellering, H. & Gruber, W. (1966) *Anal. Biochem.* 17, 369–376

- Nelson, S., Lowry, O. H. & Passonneau, J. V. (1966) in *Head Injury Conference Proceedings* (Caveness, W. F. & Walker, A. E., eds.), pp. 444-447, J. B. Lippincott, Philadelphia
- Pfeleiderer, G. (1963a) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 378-380, Academic Press, New York
- Pfeleiderer, G. (1963b) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 381-383, Academic Press, New York
- Plum, F. (1971) in *Ion Homeostasis of the Brain* (Siesjö, B. K. & Sørensen, S. C., eds.), pp. 439-454, Academic Press, New York
- Recknagel, R. O. & Potter, V. R. (1951) *J. Biol. Chem.* **191**, 263-270
- Rybova, R. (1959) *J. Neurochem.* **4**, 304-310
- Schenker, S., McCandless, D. W., Brophy, E. & Lewis, M. S. (1967) *J. Clin. Invest.* **46**, 838-848
- Schmidt, C. F. (1960) *Handb. Physiol. Sect. 1*, **3**, 1745-1750
- Sjodin, R. A. (1971) in *Biophysics and Biophysiology of Excitable Membranes* (Adelman, W. J., ed.), pp. 96-125, Van Nostrand-Reinhold, New York
- Skou, J. C. (1960) *Biochim. Biophys. Acta* **42**, 6-23
- Slein, M. W. (1963) in *Methods of Enzymatic Analysis* (Bergmeyer, H.-U., ed.), pp. 117-123, Academic Press, New York
- Tower, D. B., Wherrett, J. R. & McKhann, G. M. (1961) in *Regional Neurochemistry* (Kety, S. S. & Elkes, J., eds.), pp. 65-88, Pergamon Press, Oxford
- Van Slyke, D. D. & Neil, J. M. (1924) *J. Biol. Chem.* **56**, 523-573
- Veech, R. L., Harris, R. L., Veloso, D. & Veech, E. H. (1973) *J. Neurochem.* **20**, 183-188
- Vrba, R., Folberger, J. & Kanturek, V. (1958) *J. Neurochem.* **2**, 187-196
- Waelsch, H., Berl, S., Rossi, C. A., Clarke, D. O. & Purpura, D. P. (1964) *J. Neurochem.* **11**, 717-728
- Webster, L. T., Jr. & Gabuzda, G. J. (1958) *J. Clin. Invest.* **34**, 414-424
- Weil-Malherbe, H. (1962) in *Neurochemistry* (Elliott, K. A. C., Page, I. H. & Quastel, J. H., eds.), pp. 321-329, Charles C. Thomas, Springfield
- Whittam, R. (1964) in *Transport and Diffusion in Red Blood Cells* (Barcroft, H., Davson, H. & Paton, W. O. M., eds.), pp. 137-144, Williams and Wilkins, Baltimore
- Whittam, R. & Wheeler, K. P. (1970) *Annu. Rev. Physiol.* **32**, 21-60
- Williams, A. H., Kyu, M. H., Fenton, J. C. B. & Cavanagh, J. B. (1972) *J. Neurochem.* **19**, 1073-1077
- Williamson, D. H., Lund, P. & Krebs, H. A. (1967) *Biochem. J.* **103**, 514-527